RBC Capital Keeps a Hold Rating on Impax Laboratories

By Ryan Adsit

RBC Capital analyst Randall Stanicky reiterated a Hold rating on Impax Laboratories (NASDAQ: IPXL) on July 14 and set a price target of $15. The company’s shares closed on Friday at $16.75.

According to TipRanks.com, Stanicky is ranked 0 out of 5 stars with an average return of -7.7% and a 36.7% success rate. Stanicky covers the Healthcare sector, focusing on stocks such as Pacira Pharmaceuticals, Eagle Pharmaceuticals, and Jazz Pharmaceuticals.

Impax Laboratories has an analyst consensus of Hold, with a price target consensus of $14.40.

Based on Impax Laboratories’ latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $184 million and GAAP net loss of $98.43 million. In comparison, last year the company earned revenue of $173 million and had a GAAP net loss of $2.7 million.

Based on the recent corporate insider activity of 31 insiders, corporate insider sentiment is negative on the stock. Most recently, in May 2017, Michael Nestor, the President of IPXL sold 3,702 shares for a total of $64,962.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Impax Laboratories, Inc. operates as a technology based specialty pharmaceutical company, which engages in the development, manufacture, and marketing of controlled-release and niche generics. It operates through the Impax Generics and Impax Specialty Pharma segments.